Long-acting muscarinic antagonist/long-acting beta agonist (LAMA/LABA) combination products have recently been introduced. We sought to describe the impact of these products on patterns of chronic obstructive pulmonary disease (COPD) therapy.
This study sought to characterize the contribution of prescribed opioids to opioid-related hospitalizations across 3 provinces in Canada: British Columbia, Manitoba and Ontario.
This tool allows public access to data related to indicators for opioid prescribing in the province from 2012 onwards. It uses data from the Narcotics Monitoring System (NMS), which captures all opioid prescriptions dispensed in retail pharmacies across Ontario.
This paper describes the early impact of delisting high-strength opioid formulations in Ontario by quantifing the impact of this policy on patterns of opioid prescribing, and evaluating how this impact differed by prescriber type, opioid type and opioid strength in the first six months following policy implementation.